You are here

Article Text

Article menu
Download PDFPDF
Letter
Antinuclear and antiphospholipid autoantibodies in patients with peripheral arterial occlusive disease
  1. K Kroeger1,
  2. H Mouradi1,
  3. E Kreuzfelder2,
  4. G Rudofsky1,
  5. H Grosse-Wilde2
  1. 1Department of Angiology, University of Essen, Germany
  2. 2Institute of Immunology, University of Essen, Germany
  1. Correspondence to:
    Dr K Kröger
    Department of Angiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; knut.kroegeruni-essen.de

https://doi.org/10.1136/ard.2004.022145

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    According to the Chapel Hill Consensus Conference, large peripheral arteries are only affected by giant cell vasculitis and, in rare cases, by polyarteritis nodosa.1,2 Vasculitis becomes apparent through involvement of typical organs (lung, kidney, skin) or raised C reactive protein (CRP) level or erythrocyte sedimentation rate (ESR). Thus, a specific diagnostic effort to exclude vasculitis as an underlying disease in patients with peripheral arterial occlusive disease (PAOD) may be unnecessary. On the other hand, there is increasing evidence that humoral immunity may have a role in the pathogenesis of atherosclerosis.1,2,9 Antinuclear antibodies were reported in 70% of patients with severe coronary heart disease (CHD), compared with in only 17% in the control group.3 Thus, we prospectively studied the …

    View Full Text